Beyond PD-L1 Markers for Lung Cancer Immunotherapy

Immunotherapy using immune checkpoints inhibitors has become the standard treatment for first and second line therapy in patients with non-small cell lung cancer (NSCLC). However, proper predictive factors allowing precise qualification of NSCLC patients for immunotherapy have not been developed so...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojas-Krawczyk, Kamila, Kalinka, Ewa, Grenda, Anna, Krawczyk, Paweł, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515086/
https://www.ncbi.nlm.nih.gov/pubmed/31003463
http://dx.doi.org/10.3390/ijms20081915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515086/
https://www.ncbi.nlm.nih.gov/pubmed/31003463
http://dx.doi.org/10.3390/ijms20081915

Ejemplares similares